CAR-T Drives High Response in Relapsed/Refractory ALL

(MedPage Today) -- Heavily pretreated adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) achieved a high and durable response rate with the CAR T-cell therapy brexucabtagene autoleucel (Tecartus), according...